SciELO - Scientific Electronic Library Online

 
vol.73 issue1Primary immunodeficiencies and B-cell lymphomasRecent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Boletín médico del Hospital Infantil de México

Print version ISSN 1665-1146

Abstract

JIMENEZ-HERNANDEZ, Elva et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: response to HLH-04 treatment protocol. Bol. Med. Hosp. Infant. Mex. [online]. 2016, vol.73, n.1, pp.26-30. ISSN 1665-1146.  https://doi.org/10.1016/j.bmhimx.2015.12.007.

Introduction:

Hemophagocytic syndrome, macrophage activation syndrome, reactive histiocytosis or hemophagocytic lymphohistiocytosis (HLH) represent a group of diseases whose common thread is reactive or neoplastic mononuclear phagocytic system cells and dendritic cell proliferation.

Clinical case:

We present a case of an HLH probably associated with Epstein-Barr virus (EBV) in a 4-year-old male patient treated with HLH-04 protocol. Viral etiology in HLH is well accepted. In this case, clinical picture of HLH was assumed secondary to EBV infection because IgM serology at the time of clinical presentation was the only positive factor in the viral panel.

Conclusions:

Diagnosis of HLH is the critical first step to successful treatment. The earlier it is identified, the less the tissue damage and reduced risk of multiple organ failure, which favors treatment response.

Keywords : Hemophagocytic lymphohistiocytosis; Hemophagocytic syndrome; Epstein-Barr virus; Protocol HLH-04.

        · abstract in Spanish     · text in English     · English ( pdf )